Conference item icon

Conference item : Poster

Baricitinib provides greater improvements in patient-reported outcomes across all disease activity levels compared to placebo and adalimumab in rheumatoid arthritis

Publication status:
Published
Peer review status:
Reviewed (other)

Actions


Access Document


Files:
Publisher copy:
10.1136/annrheumdis-2021-eular.182

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDORMS
Sub department:
Botnar Research Centre
Oxford college:
St Peter's College
Role:
Author
ORCID:
0000-0001-7766-6167
Publisher:
BMJ Publishing Group
Journal:
Annals of the Rheumatic Diseases More from this journal
Volume:
80
Issue:
S1
Article number:
POS0649
Publication date:
2021-05-19
Acceptance date:
2021-04-01
Event title:
EULAR European Congress of Rheumatology 2021
Event location:
Virtual event.
Event website:
https://congress.eular.org/previous_congresses.cfm
Event start date:
2021-06-02
Event end date:
2021-06-05
DOI:
EISSN:
1468-2060
ISSN:
0003-4967
Language:
English
Keywords:
Subtype:
Poster
Pubs id:
1188118
Local pid:
pubs:1188118
Deposit date:
2021-07-29

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP